Botulinum toxin injector

Abstract

A botulinum toxin injector with a syringe has a volume marking scale that is scaled by 4 units per 0.1 mL. The volume marking scales enable unit conversion to be easy, and the possibility of excessive or insufficient botulinum toxin can be reduced. The syringe may also include additional volume marking scales configured to be interchangeably used for administration of insulin or botulinum toxin. The syringe may also include additional volume marking scales configured to be interchangeably used for administering different types of botulinum toxins.

Description

Technical Field

[0001] This utility model generally relates to a syringe for administering botulinum toxin. Background Technology

[0002] Due to availability and size considerations, insulin injectors are commonly used in the cosmetics industry for injecting botulinum toxin. One common type of insulin injector is the BD Ultrafine II. TM Needle syringe.

[0003] Insulin injectors include unit-specific volume markers based on biologically active units.

[0004] The standard and most commonly used concentration of insulin is U-100, which is 100 units of insulin per mL of liquid.

[0005] The insulin injector is manufactured in 30-unit (0.3 mL) doses, as shown in Figure 1. However, 50-unit (0.5 mL) and 100-unit (1.0 mL) doses are also available.

[0006] The required syringe size depends on the required insulin dose, where, for example, a 30-unit syringe is easier to administer a 10-unit dose compared to a 50-unit syringe.

[0007] The dosage of all commercially available botulinum toxins is also expressed in biological activity units. In female Swiss-Webster mice, one unit of botulinum toxin is equivalent to the calculated median lethal dose (LD50). 50 ).

[0008] Insulin injectors are commonly used to administer botulinum toxin. However, the unit volume scaling of insulin and botulinum toxin is incompatible, requiring a mental conversion of insulin units to botulinum toxin units during botulinum toxin administration using an insulin injector.

[0009] For example, injecting 2 units of botulinum toxin would not intuitively require a 5-unit mark on an insulin syringe. While smaller volume offsets can be more easily counted sequentially from the distal end of the syringe, it is difficult to mentally translate larger volumes, where, for example, administering 10 units of botulinum toxin would not intuitively require a 25-unit mark on an insulin syringe.

[0010] Unit conversions between scales are even more difficult. As shown in Figure 1, a 30-unit insulin syringe has a scale increment of 5, making it quite difficult to administer, for example, 9 units of botulinum toxin.

[0011] Errors in unit conversion can lead to insufficient or excessive dosage of botulinum toxin, resulting in undesirable consequences.

[0012] This invention aims to provide a method that overcomes or substantially improves at least some of the defects of the prior art, or at least provides an alternative.

[0013] It should be understood that if any prior art information is referenced herein, such reference does not constitute an acknowledgment that such information is common knowledge in the field in Australia or any other country. Utility Model Content

[0014] This article provides a botulinum toxin injector comprising a syringe having a volume marking scale scaled in 4 units per 0.1 mL, thereby avoiding the difficulties of conversion between the aforementioned units and significantly reducing the possibility of botulinum toxin overdose or underdose.

[0015] The syringe may also include additional volume markings, which are configured to be used interchangeably for administering insulin or botulinum toxin.

[0016] In a further embodiment, the syringe may also include additional volume markings configured to be interchangeably used for administering different types of botulinum toxin.

[0017] Other aspects of this utility model are also disclosed. Attached Figure Description

[0018] Although any other forms may fall within the scope of this invention, preferred embodiments of the present disclosure will now be described by way of example only with reference to the accompanying drawings, in which:

[0019] Figure 1 illustrates an insulin injector according to existing technology, such as the BD Ultrafine II. TM Needle syringes; and

[0020] Figure 2 A botulinum toxin injector according to an embodiment of the present invention is shown;

[0021] Figure 3 Another botulinum toxin injector according to an embodiment of the present invention is shown. Detailed Implementation

[0022] Figure 2 A botulinum toxin injector 100 is shown, comprising a transparent syringe 103 having a piston 101 operating therein. A needle 104 extends from the distal end of the syringe. The needle 104 is preferably a 32G 8 mm needle.

[0023] The syringe 103 includes a volume marking 102.

[0024] The volume markings 102 include scales 105 scaled in 4 units per 0.1 mL. For example, as shown in the figure, 12 units correspond to approximately 0.3 mL.

[0025] In one embodiment, a larger syringe 100 may be provided, wherein the maximum volume marking is 20, equivalent to 0.5 mL. In a further embodiment, an even larger syringe 100 may be provided, wherein the maximum volume marking is 40, equivalent to 1 mL.

[0026] The scale 105 can increase in increments of 2. In the illustrated embodiment, the volume marking scale 105 increases in increments of 2, and does not include any other scales in between.

[0027] The maximum scale of 105 can be between 8 and 16, thus providing a suitable size of measurement for typical botulinum toxin dosages. According to Figure 2 In the implementation scheme shown, the maximum scale of 105 can be 12.

[0028] When in use, syringe 100 can be used to inject multiple units of botulinum toxin according to the scale 105.

[0029] In one embodiment, the syringe 100 may include additional volume markings 102 that scale for insulin units in units of 10 units per 0.1 mL, such that the syringe 100 can be used interchangeably for insulin or botulinum toxin.

[0030] according to Figure 2 In the illustrated embodiment, volume marker 102 is designed for a specific dilution of botulinum toxin. However, Figure 3 A further embodiment is shown in which the botulinum toxin injector 100 includes additional volume markings 102A with different scales 105 for different dilutions of botulinum toxin.

[0031] Preferably, the additional volume marking 102 has a scale 105 scaled in 20 units of 0.1 mL.

[0032] Specifically, the additional volume markings are scaled in 10-unit increments and have scales 105 from 10 to 60, with 60 units corresponding to a volume of 0.3 mL. Preferably, the scales 105 of these two volume markings 102 and 102A are aligned. For example, a 2-unit scale 105 of volume marking 102 is aligned with a 10-unit scale 105 of volume marking 102A, and so on.

[0033] therefore, Figure 3The syringe allows for convenient use of 0.3 mL of botulinum toxin at a concentration of 12 units or 0.3 mL of another botulinum toxin at a concentration of 60 units. Depending on the type of botulinum toxin used with the syringe, select the appropriate volume marking 102 or 102A for use.

[0034] For the purposes of explanation, specific terminology has been used in the foregoing description to provide a thorough understanding of the present invention. However, it will be apparent to those skilled in the art that specific details are not required to practice the present invention. Therefore, for the purposes of illustration and description, the foregoing description has presented specific embodiments of the present invention. These are not intended to be exhaustive or to limit the present invention to the precise forms disclosed, as many modifications and variations are obviously possible in light of the foregoing teachings. The embodiments were chosen and described in order to best explain the principles of the present invention and its practical application, thereby enabling others skilled in the art to best utilize the present invention and various embodiments with various modifications suited to the intended particular use. The following claims and their equivalents are intended to define the scope of the present invention.

Claims

1. A botulinum toxin injector, characterized in that, The botulinum toxin injector includes a syringe having a volume scale graduated in 4 units per 0.1 mL; the maximum volume scale of the botulinum toxin injector is between 8 and 16.

2. The injector of claim 1, wherein the volume scale is graduated in 2 units.

3. The injector of claim 1, wherein the volume scale is graduated in 2 units and does not include any other scale therebetween.

4. The injector of claim 1, wherein the maximum volume scale is 12, corresponding to 0.3 mL.

5. The injector of claim 1, wherein the maximum volume scale is 20, corresponding to 0.5 mL.

6. The injector of claim 1, wherein the maximum volume scale is 40, corresponding to 1 mL.

7. The injector of claim 1, further comprising an additional volume scale graduated in 10 units per 0.1 mL.

8. The injector of claim 1, further comprising an additional volume scale having a different graduation.

9. The injector of claim 8, wherein the additional volume scale is graduated in 20 units for 0.1 mL.

10. The injector of claim 9, wherein the additional volume scale is graduated in 10 unit increments.

11. The injector of claim 10, wherein the additional volume scale has a graduation of 10 to 60.

12. The injector of claim 11, wherein the additional volume scale has a 60 unit graduation, corresponding to 0.3 mL.

13. The injector of claim 8, wherein the graduation of the volume scale and the additional volume scale are aligned.

14. The injector of claim 13, wherein the 2 unit graduation of the volume scale is aligned with the 10 unit graduation of the volume scale.

Images